

8:45 am-5:35 pm, PT

Sept. 21st **In-Person symposium**

# Advances in Cancer Therapeutics



**BioScience Forum**

**Organizers:** Toby Freedman (Synopsis Search Recruiting and Author), Joe Carlino (Carlino Consulting), Donald McCarthy (Samsara BioCapital), Betty Chang (Summit Therapeutics), Wenfeng Xu (Chantibody Therapeutics Inc), Snow Ge (BridgeBio Pharma), Shichang Miao (PBSS)



**Kelsey Gauthier, PhD**  
Director, Biology, Arcus Biosciences

Fc-Silent Anti-TIGIT Potentiates Anti-Tumor Immunity Without Depleting Regulatory T-Cells



**Allison Roberts, PhD**  
Senior Scientist, Chemical Biology, Frontier Medicines

Challenging Cancer With Chemoproteomics—FMC-376, a Dual KRAS G12C Inhibitor



**Eric Blouin**  
SVP Oncology, Ipsos Healthcare

New Regulatory Approvals for Cancer Therapeutics and Their Clinical Impact – a Commercial Perspective



**Shiva Bhowmik, PhD**  
Founder & COO, Trio Pharmaceuticals

Novel Bispecific Antibody Drugs Eliminating Cancer Cells and Immunosuppressor Cells to Enhance Anti-Tumor Immunity



**Dirk Brockstedt, PhD**  
Chief Scientific Officer, RAP T Therapeutics

Updates on CCR4 Antagonists for Oncology

**Major Sponsor**



**Jennifer Low, MD, PhD**  
Head of Therapeutics Development at 23andMe

Developing Genetically-Validated Drugs Using 23andMe's Genetic Database



**Alex Cacovean, MD**  
VP, Clinical Development at Biomea Fusion

First-in-Class Covalent MENIN Inhibitors for AML



**Umer Raffat**  
Fundamental Research Analyst, Biotech Senior Managing Director, Evercore ISI

ASCO Highlights



**Amar Patel, MD**  
Senior Director, Early Clinical Development, Bristol Myers Squibb

Advancing Novel Modalities for the Treatment of Hematologic Cancers



**Dara L. Burdette, PhD**  
Executive Director, Tempest Therapeutics

Weathering the Storm: Small Molecule Inhibitors of Diverse Targets as Novel Immune Oncology Therapies



**Cheng Liu, PhD**  
Founder, President and CEO, Eureka Therapeutics

Treating Solid Tumors with ARTEMIS T Cells Engineered with Antibody T-Cell Receptor (AbTCR)

8:45 am-5:35 pm, PT

Sept. 21st In-Person symposium

# Advances in Cancer Therapeutics



BioScience Forum

**Organizers:** Toby Freedman (Synopsis Search Recruiting and Author), Joe Carlino (Carlino Consulting), Donald McCarthy (Samsara BioCapital), Betty Chang (Summit Therapeutics), Wenfeng Xu (Chantibody Therapeutics Inc), Snow Ge (BridgeBio Pharma), Shichang Miao (PBSS)

Time (PT)	Topic
8:45-9:00 am	PBSS / BioScience Forum Welcome and Symposium Overview, <b>Shichang Miao (PBSS) &amp; Joe Carlino (BioScience Forum)</b>
9:00-9:35 am	1. Fc-Silent Anti-TIGIT Potentiates Anti-Tumor Immunity Without Depleting Regulatory T-Cells, <b>Kelsey Gauthier</b> , PhD, Director of Biology, <b>Arcus Biosciences</b>
9:35-10:10 am	2. Developing Genetically-Validated Drugs Using 23andMe's Genetic Database, <b>Jennifer Low</b> , MD, PhD, Head of Therapeutics Development, <b>23andMe</b>
10:10-10:45 am	3. Challenging Cancer With Chemoproteomics—FMC-376, a Dual KRAS G12C Inhibitor, <b>Allison Roberts</b> , PhD, Senior Scientist, Chemical Biology, <b>Frontier Medicines</b>
10:45-10:55 am	Major Sponsor's Presentation ( <b>Fortrea CRO</b> )
10:55-11:15 am	Break Period & Vendor Show
11:15-11:50 am	4. First-in-Class Covalent MENIN Inhibitors for AML, <b>Alex Cacovean</b> , MD, VP, Clinical Development, <b>Biomea Fusion</b>
11:50-12:25 pm	5. New Regulatory Approvals for Cancer Therapeutics and Their Clinical Impact – a Commercial Perspective, <b>Eric Blouin</b> , SVP Oncology, <b>Ipsos Healthcare</b>
12:25-1:15 pm	Lunch
1:15-1:50 pm	6. ASCO Highlights, <b>Umer Raffat</b> , Fundamental Research Analyst, Biotech Senior Managing Director, <b>Evercore ISI</b>
1:50-2:25 pm	7. Novel Bispecific Antibody Drugs Eliminating Cancer Cells and Immunosuppressor Cells to Enhance Anti-Tumor Immunity, <b>Shiva Bhowmik</b> , PhD, Founder & COO, <b>Trio Pharmaceuticals</b>
2:25-3:00 pm	8. Advancing Novel Modalities for the Treatment of Hematologic Cancers, <b>Amar Patel</b> , MD, Senior Director, Early Clinical Development, <b>Bristol Myers Squibb</b>
3:00-3:20 pm	Break
3:20-3:55 pm	9. Updates on CCR4 Antagonists for Oncology, <b>Dirk Brockstedt</b> , PhD, Chief Scientific Officer, <b>RAPT Therapeutics</b>
3:55-4:30 pm	10. Weathering the Storm: Small Molecule Inhibitors of Diverse Targets as Novel Immune Oncology Therapies, <b>Dara L. Burdette</b> , PhD, Executive Director, <b>Tempest Therapeutics</b>
4:30-5:05 pm	11. Treating Solid Tumors with ARTEMIS T Cells Engineered with Antibody T-Cell Receptor (AbTCR), <b>Cheng Liu</b> , PhD, Founder, President and CEO, <b>Eureka Therapeutics</b>
5:05-5:35 pm	Panel Discussion (All Speakers)
5:35-6:30 pm	Happy Hour (sponsored by <b>Alturas Analytics</b> )



Registration: <http://pbss.org/asp/eventInfo.aspx?eID=820>

San Francisco Bay Area: Crowne Plaza Foster City

8:45 am-5:35 pm, PT

Sept. 21st In-Person symposium

# Advances in Cancer Therapeutics



BioScience Forum

**Organizers:** Toby Freedman (Synopsis Search Recruiting and Author), Joe Carlino (Carlino Consulting), Donald McCarthy (Samsara BioCapital), Betty Chang (Summit Therapeutics), Wenfeng Xu (Chantibody Therapeutics Inc), Snow Ge (BridgeBio Pharma), Shichang Miao (PBSS)

## Major Sponsor



## Happy Hour Sponsor



## Vendor Show



 Registration: <http://pbss.org/asp/eventInfo.aspx?eID=820>